• Product name
  • Description
    Rabbit polyclonal to C3
  • Host species
  • Tested applications
    Suitable for: IP, RIA, WB, ELISA, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    C3 purified from human plasma

  • Positive control
    • This antibody gave a positive signal in HepG2 cell line.



Our Abpromise guarantee covers the use of ab48611 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration.
RIA Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Predicted molecular weight: 187 kDa.
ELISA Use at an assay dependent concentration.
ICC/IF Use a concentration of 5 µg/ml.


  • Function
    C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • Tissue specificity
  • Involvement in disease
    Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similarities
    Contains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • Post-translational
    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localization
  • Information by UniProt
  • Database links
  • Alternative names
    • Acylation stimulating protein cleavage product antibody
    • AHUS5 antibody
    • ARMD9 antibody
    • ASP antibody
    • C3 and PZP like alpha 2 macroglobulin domain containing protein 1 antibody
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
    • C3 antibody
    • c3 complement antibody
    • CO3_HUMAN antibody
    • Complement C3 antibody
    • Complement C3c alpha'' chain fragment 2 antibody
    • Complement component 3 antibody
    • Complement factor 3 antibody
    • CPAMD1 antibody
    • HEL S 62p antibody
    see all


  • ICC/IF image of ab48611 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab48611, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.


This product has been referenced in:
  • Wong EK  et al. Characterization of a Factor H Mutation That Perturbs the Alternative Pathway of Complement in a Family with Membranoproliferative GN. J Am Soc Nephrol N/A:N/A (2014). Human . Read more (PubMed: 24722444) »
See 1 Publication for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A


Thank you for your enquiry. I have been in touch with the source of these antibodies, and they have kindly provided the following IP protocol. Please note that this may require some further optimization in your own laboratory: IP protocol is as follows: 1. Have high binding protein A beads (from Peirce) in a column with 3 ml beads bed 2. Wash column with Glycine pH 3.5 (0.1 mM) with 2 column of volume 3. Wash 1x with 1 column volume of PBS 7.4 4. Add 400 ug of antibody to the beads and incubate for 2 hours at room temp with rotating 5. Wash with PBS 2 column volumes 6. Add cell lysates or tissue extract to the column and incubate for 2 hours at room temp. 7. Wash 2 x with PBS 8. Elute the protein and antibody with Glycine pH3.5 (0.1 mM) into the 50 ml conical tube with 250 ul of 1 M tris base as neutralization agent. (collect 25 ml) 9. Concentrate the elution liquid by lyophilization or concentrator. 10. Run SDS to determine the antigen. This method is for samples with low C3 protein expression. You can also try to coat the antibody to high binding plate and do the IP directly from the plate. The concept is similar but just smaller scale. I am sorry there are no further images to provide on this occasion. I hope this will be helpful to you. SHould you have any further questions, please do not hesitate to contact us.

Read More


Thank you for your patience in this matter. The originator of ab48611 (C3 antibody) has informed us that they have not tested this antibody against C3 breakdown products. As we discussed on the phone, I think that some of the product would recognize some of the breakdown products but this has not been confirmed. I'm sorry that I can not provide you with more information.

Read More


Sign up